Verona says sec­ond PhI­II for COPD drug hits the mark, plans 2023 NDA fil­ing

UK-based biotech Verona Phar­ma said Tues­day morn­ing that its drug, en­sifen­trine, passed its sec­ond late-stage tri­al for the com­mon lung dis­ease COPD.

In Au­gust, Verona re­port­ed the drug suc­ceed­ed in the first of its two Phase III tri­als. Now, Verona will pack­age to­geth­er the new tri­al da­ta in its ap­proval fil­ing to the FDA, which the biotech said will come in the first half of next year.

Verona’s stock $VR­NA opened around 30% above its last close, jump­ing from un­der $14 to near­ly $17.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER